2024 Outlook
The information below is subject to risks and uncertainties that may materially impact the achievement of our 2024 outlook. For more information, please refer to section ”Risk Factors” of this Annual Report for a discussion of such risks and uncertainties.
VYVGART
We filed for approval of VYVGART for gMG in several jurisdictions and we are expecting multiple decisions
YE 2024gMG seronegative trial initiation
YE 2024Japan decision on approval in ITP
1Q 2024VYVGART SC
Japan decision on approval in gMG
1Q 2024China decision on approval (Zai Lab) in gMG
YE 2024CIDP U.S. launch, if approved
Mid-Regulatory submissions for CIDP in Japan, Europe, China, Canada
YE 2024Update on PFS development in MG and CIDP
1H 2024Efgartigimod
Proof of concept data in SjD
1H 2024Proof of concept data in POTS post-COVID-19
1H 2024Proof of concept data in Myositis
2H 2024Empasiprubart, ARGX-119 and IIP
Empasiprubart
Full Phase 2 data in MMN
2024ARGX-119
Phase 1b/2a study initiations in CMS and ALS
2024Immunology Innovation Program (IIP)
4 INDs filed
YE 2025